Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers

Inclusion Criteria: * Male or female Caucasian subject ≥ 18 and ≤ 50 years; * Good general health (by medical history and physical examination); * For male and female subjects of childbearing potential use a double contraception method; * For female subjects of childbearing potential only: negative plasma pregnancy test at Screening and at admission in the clinical unit; * Body mass index (BMI) ≥18 and ≤ 27 kg/m2; * No clinically relevant abnormalities in blood pressure and heart rate; * No clinically relevant abnormalities in 12-lead ECG results; * No clinically relevant abnormalities in results of laboratory tests; * Registered with the French Social Security in agreement with the French law on biomedical experimentation. Exclusion Criteria: * A predictable poor compliance or inability to communicate well with the Investigator; * Unsuitable veins for repeated venipuncture. * Evidence of clinically relevant cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric diseases as judged by the Investigator; * A history of additional risk factors for Torsades des Pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome); * The use of concomitant medications that prolong the QT/QTc interval; * Any condition requiring regular concomitant medication, including herbal products and over-the-counter (OTC) medication or predicted need of any concomitant medication during the study; * Evidence of any clinically significant acute or chronic disease, including known or suspected HIV, hepatitis B virus (HBV) and HCV infection; * History of relevant clinical allergic reactions of any origin; * Known hypersensitivity to any of the test materials or related compounds; * Intake of any medication (except paracetamol, hormonal contraceptives and hormone replacement therapy for postmenopausal women), including OTC medications and herbal products that could affect the outcome of the study, within 2 weeks prior to the first drug administration or less than 5 times the t1/2 of that drug, whichever is the longer; * Drug abuse; * Current use of nicotine containing products and the inability to stop using nicotine containing products during confinement in the clinical centre. * Use of caffeine containing beverages exceeding 500 mg caffeine/day and the inability to refrain from the use of caffeine containing beverages during confinement in the clinical centre; * Intake of any food or any beverage containing grapefruit or grapefruit juice, orange or pomelo juice within 48 h prior to the first dosing and the inability to stop such intake during the study; * Blood donation or loss of significant amount of blood within three months prior to the first dosing; * Positive drug screen; * Positive serology to HIV (HIV1 and HIV2) and/or HCV antibodies, and/or hepatitis B surface antigen (HBsAG); * Any other condition that in the opinion of the Investigator would interfere with the evaluation of the results or constitute a health risk for the subject; * Participation in a drug study within 3 months prior to the first dosing.